belinostat + atazanavir

Belinostat + atazanavir is a theoretical combination of two approved drugs: **belinostat**, a histone deacetylase (HDAC) inhibitor primarily used for relapsed or refractory peripheral T-cell lymphoma (PTCL)[2][4], and **atazanavir**, an HIV-1 protease inhibitor used in combination with other antiretroviral drugs for treatment of HIV-1 infection[1]. No branded or generic combination product exists for these drugs, and the combination is contraindicated due to significant pharmacokinetic interaction where atazanavir (a strong UGT1A1 inhibitor) can markedly increase serum levels of belinostat, thereby increasing risk of toxicity[3][4]. No legitimate pharmaceutical product or trial utilizes this specific combination due to its risk.